Advertisement

Breast Cancer Research and Treatment

, Volume 155, Issue 3, pp 457–462 | Cite as

HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline

  • Yao-Shan Fan
  • Carmen E. Casas
  • Jinghong Peng
  • Melanie Watkins
  • Lynn Fan
  • Jennifer Chapman
  • Offiong Francis Ikpatt
  • Carmen Gomez
  • Wei Zhao
  • Isildinha M. Reis
Preclinical study

Abstract

The status of human epidermal growth factor receptor 2 (HER2, ERBB2) determines the eligibility of breast cancer patients to receive HER2-targeted therapy. The majority of HER2 testing in the U.S. is performed using a combination of immunohistochemistry (IHC) screening followed by fluorescence in situ hybridization (FISH) for IHC equivocal cases. In 2013, the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) updated the guideline for HER2 testing. This study evaluates the impact of the 2013 ASCO/CAP updated guideline on final HER2 FISH classification of breast cancers with an equivocal IHC result. For each case, we reported a FISH result according to the 2013 updated guideline and recorded a separated result using the 2007 guideline for investigational purpose. McNemar’s test and Bowker’s symmetry test were used to compare the classifications by the two guidelines. Among 172 HER2 IHC 2+ equivocal cases, use of the 2103 guideline changed classifications in 36 cases (21 %) when compared with the results expected by use of the 2007 guideline, and yielded a higher proportion of positive (28.5 vs. 23.3 %) and equivocal (16.3 vs. 4.1 %), and a lower proportion of negative (55.2 vs. 72.7 %) cases (p < 0.001). The major classification change with use of the updated guideline is from the HER2 FISH negative to equivocal in 26 cases (15 %). Our study has shown that implementation of the 2013 ASCO/CAP updated guideline has significant impact on HER2 classification for breast cancers with an equivocal HER2 IHC result and therefore increased the use of HER2-targeted therapy. Our data have also shown that reflex FISH is effective for final classification of the IHC equivocal cases and that polysomy 17 (CEP17 copy number ≥3/cell) is present in a significantly higher proportion of cases with an equivocal HER2 FISH classification.

Keywords

Breast cancer HER2 Immunohistochemistry Fluorescence in situ hybridization ASCO/CAP practice guideline Polysomy 17 

Notes

Compliance with ethical standards

Conflict of interest

All authors declare that they no have no conflict interest.

References

  1. 1.
    Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN (2009) The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14(4):320–368CrossRefPubMedGoogle Scholar
  2. 2.
    Gajria D, Chandarlapaty S (2011) HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther 11(2):263–275PubMedCentralCrossRefPubMedGoogle Scholar
  3. 3.
    Sapino A, Goia M, Recupero D, Marchiò C (2013) Current challenges for HER2 testing in diagnostic pathology: state of the art and controversial issues. Front Oncol 3:129. doi: 10.3389/fonc.2013.00129 PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF, American Society of Clinical Oncology/College of American Pathologists (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131(1):18–43PubMedGoogle Scholar
  5. 5.
    Paik S, Bryant J, Tan-Chiu E, Romond E, Hiller W, Park K, Brown A, Yothers G, Anderson S, Smith R, Wickerham DL, Wolmark N (2002) Real-world performance of HER2 testing–national surgical adjuvant breast and bowel project experience. J Natl Cancer Inst 94(11):852–854CrossRefPubMedGoogle Scholar
  6. 6.
    Roche PC, Suman VJ, Jenkins RB, Davidson NE, Martino S, Kaufman PA, Addo FK, Murphy B, Ingle JN, Perez EA (2002) Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 94(11):855–857CrossRefPubMedGoogle Scholar
  7. 7.
    Perez EA, Suman VJ, Davidson NE, Martino S, Kaufman PA, Lingle WL, Flynn PJ, Ingle JN, Visscher D, Jenkins RB (2006) HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 24(19):3032–3038CrossRefPubMedGoogle Scholar
  8. 8.
    Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M, Turpeenniemi-Hujanen T, Jyrkkiö S, Flander M, Helle L, Ingalsuo S, Johansson K, Jääskeläinen AS, Pajunen M, Rauhala M, Kaleva-Kerola J, Salminen T, Leinonen M, Elomaa I, Isola J, FinHer Study Investigators (2006) Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354(8):809–820CrossRefPubMedGoogle Scholar
  9. 9.
    Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF, American Society of Clinical Oncology, College of American Pathologists (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31(31):3997–4013CrossRefPubMedGoogle Scholar
  10. 10.
    Lal P, Salazar PA, Hudis CA, Ladanyi M, Chen B (2004) HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring. Am J Clin Pathol 121(5):631–636CrossRefPubMedGoogle Scholar
  11. 11.
    Owens MA, Horten BC, Da Silva MM (2004) HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 5(1):63–69CrossRefPubMedGoogle Scholar
  12. 12.
    Press MF, Sauter G, Bernstein L, Villalobos IE, Mirlacher M, Zhou JY, Wardeh R, Li YT, Guzman R, Ma Y, Sullivan-Halley J, Santiago A, Park JM, Riva A, Slamon DJ (2005) Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 11(18):6598–6607CrossRefPubMedGoogle Scholar
  13. 13.
    Tubbs RR, Hicks DG, Cook J, Downs-Kelly E, Pettay J, Hartke MB, Hood L, Neelon R, Myles J, Budd GT, Moore HC, Andresen S, Crowe JP (2007) Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 Status in adenocarcinoma of the breast: a single institution experience. Diagn Mol Pathol 16(4):207–210CrossRefPubMedGoogle Scholar
  14. 14.
    Dendukuri N, Khetani K, McIsaac M, Brophy J (2007) Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis. CMAJ 176(10):1429–1434PubMedCentralCrossRefPubMedGoogle Scholar
  15. 15.
    Perez EA, Baweja M (2008) HER2-positive breast cancer: current treatment strategies. Cancer Invest 26(6):545–552CrossRefPubMedGoogle Scholar
  16. 16.
    Hicks DG, Kulkarni S (2008) Trastuzumab as adjuvant therapy for early breast cancer: the importance of accurate human epidermal growth factor receptor 2 testing. Arch Pathol Lab Med 132(6):1008–1015PubMedGoogle Scholar
  17. 17.
    Lidgren M, Wilking N, Jönsson B, Rehnberg C (2008) Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer. Acta Oncol 47(6):1018–1028CrossRefPubMedGoogle Scholar
  18. 18.
    Manion E, Hornick JL, Lester SC, Brock JE (2011) A comparison of equivocal immunohistochemical results with anti-HER2/neu antibodies A0485 and SP3 with corresponding FISH results in routine clinical practice. Am J Clin Pathol 135(6):845–851CrossRefPubMedGoogle Scholar
  19. 19.
    Lee AH, Key HP, Bell JA, Hodi Z, Ellis IO (2011) Breast carcinomas with borderline (2 +) HER2 immunohistochemistry: percentage of cells with complete membrane staining for HER2 and the frequency of HER2 amplification. J Clin Pathol 64(6):490–492CrossRefPubMedGoogle Scholar
  20. 20.
    Atkinson R, Mollerup J, Laenkholm AV, Verardo M, Hawes D, Commins D, Engvad B, Correa A, Ehlers CC, Nielsen KV (2011) Effects of the change in cutoff values for human epidermal growth factor receptor 2 status by immunohistochemistry and fluorescence in situ hybridization: a study comparing conventional brightfield microscopy, image analysis-assisted microscopy, and interobserver variation. Arch Pathol Lab Med 135(8):1010–1016CrossRefPubMedGoogle Scholar
  21. 21.
    Vergara-Lluri ME, Moatamed NA, Hong E, Apple SK (2012) High concordance between HercepTest immunohistochemistry and ERBB2 fluorescence in situ hybridization before and after implementation of American Society of Clinical Oncology/College of American Pathology 2007 guidelines. Mod Pathol 25(10):1326–1332CrossRefPubMedGoogle Scholar
  22. 22.
    Green IF, Zynger DL (2015) Institutional quality assurance for breast HER2 immunohistochemical testing: identification of outlier results and impact of simultaneous fluorescence in situ hybridization cotesting. Hum Pathol 46(12):1842–1849CrossRefPubMedGoogle Scholar
  23. 23.
    Long TH, Lawce H, Durum C, Moore SR, Olson SB, Gatter K, Troxell ML (2015) The New Equivocal: changes to HER2 FISH Results When Applying the 2013 ASCO/CAP Guidelines. Am J Clin Pathol 144(2):253–262CrossRefPubMedGoogle Scholar
  24. 24.
    Muller KE, Marotti JD, Memoli VA, Wells WA, Tafe LJ (2015) Impact of the 2013 ASCO/CAP HER2 guideline updates at an Academic Medical Center that performs primary HER2 FISH testing: increase in equivocal results and utility of reflex immunohistochemistry. Am J Clin Pathol 144(2):247–252CrossRefPubMedGoogle Scholar
  25. 25.
    Zhang H, Ren G, Wang X, Zhao J, Yao H, Bai Y, Bo W (2012) HER-2 gene amplification by fluorescence in situ hybridization (FISH) compared with immunohistochemistry (IHC) in breast cancer: a study of 528 equivocal cases. Breast Cancer Res Treat 134(2):743–749CrossRefPubMedGoogle Scholar
  26. 26.
    Hanna WM, Rüschoff J, Bilous M, Coudry RA, Dowsett M, Osamura RY, Penault-Llorca F, van de Vijver M, Viale G (2014) HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity. Mod Pathol 27(1):4–18CrossRefPubMedGoogle Scholar
  27. 27.
    Orsaria M, Khelifa S, Buza N et al (2013) Chromosome 17 polysomy: correlation with histological parameters and HER2NEU gene amplification. J Clin Pathol 66:1070–1075CrossRefPubMedGoogle Scholar
  28. 28.
    Moelans CB, van Diest PJ (2014) CEP17 copy number increase does not indicate polysomy 17. J Clin Pathol 67(5):454–455CrossRefPubMedGoogle Scholar
  29. 29.
    Rondón-Lagos M, Verdun Di Cantogno L, Rangel N, Mele T, Ramírez-Clavijo SR, Scagliotti G, Marchiò C, Sapino A (2014) Unraveling the chromosome 17 patterns of FISH in interphase nuclei: an in-depth analysis of the HER2 amplicon and chromosome 17 centromere by karyotyping, FISH and M-FISH in breast cancer cells. BMC Cancer 14:922. doi: 10.1186/1471-2407-14-922 PubMedCentralCrossRefPubMedGoogle Scholar
  30. 30.
    Jang MH, Kim EJ, Kim HJ, Chung YR, Park SY (2015) Assessment of HER2 status in invasive breast cancers with increased centromere 17 copy number. Breast Cancer Res Treat 153(1):67–77CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Yao-Shan Fan
    • 1
  • Carmen E. Casas
    • 1
  • Jinghong Peng
    • 1
  • Melanie Watkins
    • 1
  • Lynn Fan
    • 1
  • Jennifer Chapman
    • 1
  • Offiong Francis Ikpatt
    • 1
  • Carmen Gomez
    • 1
  • Wei Zhao
    • 3
  • Isildinha M. Reis
    • 2
    • 3
  1. 1.Department of Pathology and Laboratory MedicineUniversity of Miami Miller School of MedicineMiamiUSA
  2. 2.Department of Public Health SciencesUniversity of Miami Miller School of MedicineMiamiUSA
  3. 3.Biostatistics and Bioinformatics Core Shared Resource, Sylvester Comprehensive Cancer CenterUniversity of Miami School of MedicineMiamiUSA

Personalised recommendations